4.3 Review

Cystic fibrosis in young children: A review of disease manifestation, progression, and response to early treatment

期刊

JOURNAL OF CYSTIC FIBROSIS
卷 15, 期 2, 页码 147-157

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jcf.2015.09.008

关键词

Child; Disease progression; Comprehensive survey; Data collection; Infant; Preschool; Health status

资金

  1. Vertex Pharmaceuticals Incorporated, Boston, Massachusetts

向作者/读者索取更多资源

Background: Studies have described illness associated with cystic fibrosis (CF) early in life, but there is no comprehensive accounting of the prevalence and ages of disease manifestation and progression described in individual studies. Methods: We searched for peer-reviewed English-language studies of the health of children 6 years old with CF (published 1990-2014). Structural abnormalities and dysfunction of the digestive and respiratory systems were summarized across relevant studies by system and age group. Results: Primary studies (125 total) from 22 countries described abnormalities, dysfunction, and disease progression in infancy and early childhood. Improved health was consistently observed in association with diagnosis via newborn screening compared with cohorts diagnosed later by symptomatic presentation. Conclusions: The peer-reviewed literature is remarkably consistent: CF-associated growth impairment and airway abnormalities are reported at birth, and disease progression is reported in infancy and throughout childhood. Earlier access to routine CF management is associated with improved subsequent health status. (C) 2015 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Respiratory System

The use of antimicrobial susceptibility testing in fibrosis pulmonary exacerbations

Jonathan D. Cogen, Kathryn B. Whitlock, Ronald L. Gibson, Lucas R. Hoffman, Donald R. VanDevanter

JOURNAL OF CYSTIC FIBROSIS (2019)

Article Pediatrics

Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis

Jeffrey S. Wagener, Donald R. VanDevanter, Michael W. Konstan, David J. Pasta, Stefanie J. Millar, Wayne J. Morgan

PEDIATRIC PULMONOLOGY (2020)

Article Respiratory System

Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)

M. W. Konstan, D. R. VanDevanter, S. M. Rowe, M. Wilschanski, E. Kerem, I Sermet-Gaudelus, E. DiMango, P. Melotti, J. McIntosh, K. De Boeck

JOURNAL OF CYSTIC FIBROSIS (2020)

Article Respiratory System

Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis

Donald R. VanDevanter, Sonya L. Heltshe, Jay B. Hilliard, Michael W. Konstan

Summary: The study investigated the relationships between Pseudomonas aeruginosa (Pa) isolate AST results, antipseudomonal PEx treatments, and treatment responses. The findings suggest that complete Pa coverage did not show superior responses compared to lesser coverage treatments, indicating that AST may have limited utility in selecting antimicrobials for CF PEx treatment.

JOURNAL OF CYSTIC FIBROSIS (2021)

Article Respiratory System

Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials

Donald R. VanDevanter, Nicole Mayer Hamblett, Noah Simon, Joseph McIntosh, Michael W. Konstan

Summary: The study compared respiratory events (RE) observed during a 48-week trial of ataluren across six exacerbation definitions. It found that missingness of criteria in Fuchs definitions and the presence of criteria were associated with clinician exacerbation assessment.

JOURNAL OF CYSTIC FIBROSIS (2021)

Article Respiratory System

Antimicrobial resistance: Concerns of healthcare providers and people with CF

Wendy Bullington, Sarah Hempstead, Alan R. Smyth, Pavel Drevinek, Lisa Saiman, Valerie J. Waters, Scott C. Bell, Donald R. VanDevanter, Patrick A. Flume, Stuart Elborn, Marianne S. Muhlebach

Summary: The study evaluated the attitudes of healthcare providers and people with cystic fibrosis or their parents towards antimicrobial resistance (AMR) internationally. Findings showed that both groups are concerned about AMR, with Pseudomonas spp. and Burkholderia spp. being the most concerning organisms. There was a discrepancy in AMR education discussions between healthcare providers and people with cystic fibrosis.

JOURNAL OF CYSTIC FIBROSIS (2021)

Review Respiratory System

Building global development strategies for cf therapeutics during a transitional cftr modulator era

N. Mayer-Hamblett, S. Van Koningsbruggen-Rietschel, D. P. Nichols, D. R. VanDevanter, J. C. Davies, T. Lee, A. G. Durmowicz, F. Ratjen, M. W. Konstan, K. Pearson, S. C. Bell, J. P. Clancy, J. L. Taylor-Cousar, K. De Boeck, S. H. Donaldson, D. G. Downey, P. A. Flume, P. Drevinek, C. H. Goss, I Fajac, A. S. Magaret, B. S. Quon, S. M. Singleton, J. M. VanDalfsen, G. Z. Retsch-Bogart

JOURNAL OF CYSTIC FIBROSIS (2020)

Article Respiratory System

Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment

D. R. VanDevanter, S. L. Heltshe, D. B. Sanders, N. E. West, M. Skalland, P. A. Flume, C. H. Goss

Summary: This study evaluates the changes in CRISS during intravenous antimicrobial exacerbation treatments and finds that CRISS reduction is associated with higher baseline CRISS and younger age of subjects. CRISS may serve as an effective endpoint for PEx interventional trials.

JOURNAL OF CYSTIC FIBROSIS (2021)

Review Pediatrics

Epidemiologic Study of Cystic Fibrosis: 25 years of observational research

Michael W. Konstan, David J. Pasta, Donald R. VanDevanter, Jeffrey S. Wagener, Wayne J. Morgan

Summary: The Epidemiologic Study of Cystic Fibrosis (ESCF) was a large-scale observational study conducted on cystic fibrosis patients, collecting extensive data on disease characteristics, treatment outcomes, and survival rates. The study has facilitated the updating of CF patient genotype and survival information, providing valuable insights for patient care practices and future data registries.

PEDIATRIC PULMONOLOGY (2021)

Review Microbiology

Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis

J. Stuart Elborn, Patrick A. Flume, Donald R. Van Devanter, Claudio Procaccianti

Summary: Patients with cystic fibrosis are highly susceptible to bacterial infections of the airways, particularly chronic Pseudomonas aeruginosa. Long-term use of inhaled antimicrobials is standard care for reducing exacerbation frequency and improving quality of life. Levofloxacin has been approved as an inhaled solution for the treatment of chronic P. aeruginosa infections in CF patients in Europe and Canada.

FUTURE MICROBIOLOGY (2021)

Article Respiratory System

Antipseudomonal treatment decisions during CF exacerbation management

D. R. VanDevanter, N. E. West, D. B. Sanders, M. Skalland, C. H. Goss, P. A. Flume, S. L. Heltshe

Summary: The study found that there is no additional benefit when multiple antipseudomonal classes are used to treat pulmonary exacerbation in people with cystic fibrosis and Pseudomonas aeruginosa infection.

JOURNAL OF CYSTIC FIBROSIS (2022)

Article Respiratory System

Changes in airway bacterial communities occur soon after initiation of antibiotic treatment of pulmonary exacerbations in cystic fibrosis

Lisa A. Carmody, Linda M. Kalikin, Donald R. VanDevanter, Gen Li, Kristopher Opron, Richard H. Simon, Lindsay J. Caverly, John J. LiPuma

Summary: Chronic polymicrobial airway infections are common in patients with cystic fibrosis (CF). This study analyzed sputum samples from CF patients before and during antibiotic treatment for pulmonary exacerbations (PEx). The peak impact of antibiotic treatment was observed on the fourth or fifth day.

JOURNAL OF CYSTIC FIBROSIS (2022)

Article Respiratory System

Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosi

Kevin W. Southern, Carlo Castellani, Elise Lammertyn, Alan Smyth, Donald VanDevanter, Silke van Koningsbruggen-Rietschel, Juerg Barben, Amanda Bevan, Edwin Brokaar, Sarah Collins, Gary J. Connett, Thomas W. V. Daniels, Jane Davies, Dimitri Declercq, Silvia Gartner, Andrea Gramegna, Naomi Hamilton, Jenny Hauser, Nataliya Kashirskaya, Laurence Kessler, Jacqueline Lowdon, Halyna Makukh, Clemence Martin, Lisa Morrison, Dilip Nazareth, Jacquelien Noordhoek, Ciaran O'Neill, Elizabeth Owen, Helen Oxley, Karen S. Raraigh, Caroline Raynal, Karen Robinson, Jobst Roehmel, Carsten Schwarz, Isabelle Sermet, Michal Shteinberg, Ian Sinha, Constance Takawira, Peter van Mourik, Marieke Verkleij, Michael D. Waller, Alistair Duff

Summary: Cystic fibrosis (CF) has entered the era of variant-specific therapy, tailored to the genetic variants in the CFTR gene, and CFTR modulators, the first available therapy, have transformed CF management. Interim standards have been produced to guide healthcare professionals in providing variant-specific therapy for CF patients using evidence-based guidance and stakeholder consultation.

JOURNAL OF CYSTIC FIBROSIS (2023)

Article Respiratory System

Willingness of people with cystic fibrosis receiving elexacaf tor/tezacaf tor/ivacaf tor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials

D. R. Vandevanter, E. T. Zemanick, M. W. Konstan, C. L. Ren, K. Odem-Davis, I. Emerman, J. Young, N. Mayer-Hamblett

Summary: This study assessed the feasibility of enrolling CF patients using ETI in clinical trials of new modulators and inhaled antimicrobials (inhABX). The results showed that study designs and previous clinical trial experience influenced the willingness of participants. This has implications for the feasibility of future clinical trials.

JOURNAL OF CYSTIC FIBROSIS (2023)

Review Biochemistry & Molecular Biology

Sigma-2 Receptors-From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases

Britney N. Lizama, Jennifer Kahle, Susan M. Catalano, Anthony O. Caggiano, Michael Grundman, Mary E. Hamby

Summary: There is a significant medical need to develop disease-modifying treatment options for age-related degenerative diseases of the central nervous system. The sigma-2 receptor plays a role in regulating cell functions and has potential as a therapeutic target for Alzheimer's disease, a-synucleinopathies, and dry age-related macular degeneration.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

暂无数据